Literature DB >> 17653857

Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.

Carsten T Viehl1, Daniel M Frey, Chanpheng Phommaly, Tingting Chen, Timothy P Fleming, William E Gillanders, Timothy J Eberlein, Peter S Goedegebuure.   

Abstract

BACKGROUND: Mammaglobin-A (MGB) is a breast cancer-associated antigen that is an attractive target for immune intervention. MGB has been shown to induce a specific CD8 T cell response in breast cancer patients, but little is known about a possible MGB-specific CD4 T cell response.
METHODS: Peripheral blood-derived CD4(+)CD25(-) T cells were stimulated in vitro with MGB-pulsed antigen-presenting cells (APC). The MGB and human leukocyte antigen (HLA) class II specificity of the CD4 T cell lines was confirmed by cytokine release following restimulation with autologous and allogenic APC pulsed with MGB from different sources. Candidate HLA class II-restricted epitopes were identified by computer algorithm and validated in cytokine release assays.
RESULTS: MGB-specific CD4 T cells were successfully generated in cultures from six of seven donors. Restimulation of MGB-specific CD4 T cells with MGB-pulsed APC induced significantly higher levels of interferon (IFN)-gamma release than APC pulsed with an irrelevant protein (P = 0.0004). Cultures from five of seven donors showed a pure Th1 type response as evidenced by the absence of interleukin (IL)-4. MGB-specific CD4 T cells recognized both recombinant and naturally processed MGB presented by APC. This recognition was HLA class II-restricted, as HLA-DR mismatched APC were not recognized. MGB-specific CD4 T cells from three of four donors recognized MGB-derived, HLA class II-restricted peptides pulsed onto APC.
CONCLUSIONS: We have successfully generated MGB-specific CD4 T cell cultures and identified candidate MGB HLA class II epitopes. These studies should facilitate study of the CD4 T cell response to MGB, and the development and monitoring of vaccine strategies targeting this unique antigen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653857     DOI: 10.1007/s10549-007-9657-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Authors:  Lijin Li; John M Herndon; Steven M Truscott; Ted H Hansen; Timothy P Fleming; Peter Goedegebuure; William E Gillanders
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

2.  Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes.

Authors:  S D Soysal; S Muenst; J Kan-Mitchell; E Huarte; X Zhang; I Wilkinson-Ryan; T Fleming; V Tiriveedhi; T Mohanakumar; L Li; J Herndon; D Oertli; S P Goedegebuure; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2014-09-12       Impact factor: 4.872

3.  HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.

Authors:  Bently Patrick Doonan; Azizul Haque
Journal:  Open Cancer Immunol J       Date:  2010-01-01

Review 4.  Human mammaglobin in breast cancer: a brief review of its clinical utility.

Authors:  Fawwaz Shakir Al Joudi
Journal:  Indian J Med Res       Date:  2014-05       Impact factor: 2.375

5.  HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.

Authors:  Hans-Henning Schmidt; Yingzi Ge; Felix J Hartmann; Heinke Conrad; Felix Klug; Sina Nittel; Helga Bernhard; Christoph Domschke; Florian Schuetz; Christof Sohn; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2013-05-15       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.